Please Wait
Applying Filters...
menu
    • menu
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Therapeutics Reports Q1 2026 Results
    Allarity Therapeutics Reports Q1 2026 Results

    15 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/15/3296144/0/en/allarity-therapeutics-reports-first-quarter-2026-results-and-continued-stenoparib-development-in-multiple-cancers.html

    GLOBENEWSWIRE
    15 May 2026
    Share Share
    Allarity Advances Stenoparib with Phase 3 Manufacturing Campaign
    Allarity Advances Stenoparib with Phase 3 Manufacturing Campaign

    05 May 2026

    // GLOBENEWSWIRE

    https://ml-eu.globenewswire.com/Resource/Download/8e3efa27-2bfe-4ede-b409-a1262c03a531

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Allarity's Stenoparib DRP Test Gets U.S. Patent Allowance
    Allarity's Stenoparib DRP Test Gets U.S. Patent Allowance

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3281537/0/en/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-a-notice-of-allowance-from-the-us-patent-and-trademark-office.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    Allarity Presents Two AACR Posters on Stenoparib, DRP Data
    Allarity Presents Two AACR Posters on Stenoparib, DRP Data

    21 Apr 2026

    // PRESS RELEASE

    https://allarity.com/press-release/allarity-therapeutics-presents-two-aacr-2026-posters-highlighting-stenoparibs-potential-in-colorectal-cancer-as-well-as-new-predictive-data-linking-drp-and-overall-survival-in-ovarian-c/

    PRESS RELEASE
    21 Apr 2026
    Share Share
    Allarity Therapeutics Secures $20M for Stenoparib's FDA Approval
    Allarity Therapeutics Secures $20M for Stenoparib's FDA Approval

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3250989/0/en/Allarity-Therapeutics-Closes-20-Million-Financing-to-Accelerate-the-Advance-of-Stenoparib-Toward-FDA-Approval-and-Commercialization.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230960/0/en/Allarity-Therapeutics-announces-that-its-collaborative-Phase-2-trial-with-the-United-States-Veteran-s-Administration-Combining-Stenoparib-with-Temozolomide-in-Relapsed-Small-Cell-L.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.